|
Aethlon Medical and Commonwealth Biotechnologies Sign
Cooperative Research Agreement
SAN DIEGO--March 29, 2006--Aethlon Medical, Inc. (OTCBB: AEMD), a pioneer in
developing therapeutic devices for infectious disease, announced today that
it has signed a cooperative research agreement with Commonwealth
Biotechnologies, Inc. (CBI). Under the agreement, Aethlon and CBI will
collaborate to pursue federal grant and research opportunities for the
Aethlon Hemopurifier(TM) within biodefense and pandemic preparedness
programs. Since 1999, Commonwealth researchers have managed or participated
in awarded biodefense grants exceeding $20,000,000 in value. CBI also
operates a secure BSL-3 containment facility able to receive and work with
select agents as defined by the Centers for Disease Control (CDC).
"In addition to its obvious value as a treatment for acute viral infections,
the Hemopurifier(TM) technology developed by Aethlon has enormous potential
as a device to manage exposure to the viral agents identified by the CDC and
other agencies as biothreat agents. It is simple in concept, straightforward
in design, and has been shown to be effective in removing and trapping a
variety of viruses," said Dr. Richard J. Freer, Chairman & COO of CBI. "We
view this partnership as a natural to bring technology and expertise
together to provide a very strong package for presentation to the many
agencies, including the Department of Homeland Security, concerned with the
threat of bioterrorism," concluded Dr. Freer.
James A. Joyce, Chairman & CEO of Aethlon, stated: "Our colleagues at
Commonwealth have an established record of securing grant income related to
government sponsored biodefense initiatives." Joyce concluded: "We look
forward to leveraging the resources of both organizations as a means to
advance the commercialization of our Hemopurifier(TM) as a broad-spectrum
treatment against evolving pandemic and bioweapon threats."
About Aethlon Medical
Aethlon Medical is developing the first medical device to treat infectious
disease. The device, known as the Hemopurifier(TM), is a broad-spectrum
treatment countermeasure against drug and vaccine resistant bioweapons,
naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic
infectious disease targets including Hepatitis-C (HCV) and the Human
Immunodeficiency Virus (HIV). Aethlon has also initiated research on a
second generation Hemopurifier(TM) that targets the capture of growth
factors inherent in the spread of Cancer. More information on Aethlon
Medical and the Hemopurifier(TM) technology can be found at
www.aethlonmedical.com.
About Commonwealth Biotechnologies
Commonwealth Biotechnologies, Inc. is a solutions provider to the global
biotechnology industry, academic institutions, government agencies, and
pharmaceutical companies. It offers broad ranging expertise and a complete
array of the most current analytical and synthetic chemistries and
biophysical analysis technologies, many of which are not available from
other commercial sources. CBI has crafted a stimulating, open environment
where scientists collaborate among themselves and with its clients, take on
interesting challenges and develop creative solutions. Through its FIL
division, CBI offers comprehensive genetic identity testing, including
paternity, forensic, and CODIS analyses. CBI is accredited by the American
Association of Blood Banks, CLIA, and the National Forensic Science
Technology Council, and operates fully accredited BSL-3 laboratory. For more
information, visit CBI on the web at
www.cbi-biotech.com.
Certain of the statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical, Inc to be
materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the development
of its planned products, the ability of the Company to obtain FDA and other
regulatory approvals permitting the sale of its products, the Company's
ability to manufacture its products and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a variety
of factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the Company's
Securities and Exchange Commission filings.
Contact:
Aethlon Medical, Inc.
Jeff Richardson, 858-459-7800 x302
jrichardson@aethlonmedical.com
or
James A. Joyce, 858-459-7800 x301
jj@aethlonmedical.com
--------------------------------------------------------------------------------
Source: Aethlon Medical, Inc.
|
|
